Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AF0150; AFO 150; Imagent; Imavist

Latest Information Update: 09 Dec 2004

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IMCOR Pharmaceutical
  • Class Fluorocarbons; Imaging agents; Small molecules
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Cardiovascular disorders

Most Recent Events

  • 09 Dec 2004 IMCOR commenced a phase II study investigating alternative methods of administration for perflexane such as repeat dosing and infusion
  • 12 Feb 2004 Photogen Technologies is now called IMCOR Pharmaceutical
  • 22 Dec 2003 Perflexane has been licensed to Kyosei Pharmaceutical Co. Ltd. for radiology and cardiology indications in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top